Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Solid Science
Charlestown, Massachusetts, United Statescorealispharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate SGT‑003 in Phase 1/2 for Duchenne muscular dystrophy. Other programs are in preclinical or discovery stages targeting rare neuromuscular and cardiac diseases. The company also develops enabling platform technologies to improve gene therapy delivery and efficacy.
- Therapeutic areas
- CardiovascularRare DiseasesNeurology
- Modalities
- Gene therapyBiologic (via gene delivery)Platform technologies for genetic regulators and capsid engineering
- Industry
- Biotech
02
Partnerships
Ultragenyx Pharmaceutical Inc.University of Washington (license agreement)University of Missouri (license agreement)University of Florida (license agreement)ICS Maugeri S.p.A. (license agreement)
Beyond the preview
Go deeper on Solid Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solid Science.